IPSEN, OOO
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1929-01-01
- Employees
- 5.7K
- Market Cap
- $9.8B
- Website
- https://www.ipsen.com/
Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome
Phase 3
Terminated
- Conditions
- Malignant Carcinoid Syndrome
- First Posted Date
- 2004-09-27
- Last Posted Date
- 2020-04-30
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 4
- Registration Number
- NCT00092287
- Locations
- 🇺🇸
Larry Kvols, MD, Tampa, Florida, United States
Diflomotecan (BN80915) Administered Once Every 3 Weeks in Treating Patients With Sensitive Small Cell Lung Cancer (SCLC)
Phase 2
Completed
- Conditions
- Small Cell Lung Cancer
- First Posted Date
- 2004-03-23
- Last Posted Date
- 2020-04-29
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 9
- Registration Number
- NCT00080015
© Copyright 2025. All Rights Reserved by MedPath